Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
about
Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycosesLimited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in ratsEnhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige miceIn vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with IntralipidClinical Translation of Nanomedicine.Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Unusual lipid structures selectively reduce the toxicity of amphotericin B.Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsLiposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholateAmphotericin B: delivery systems.Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice.Carrier effects on biological activity of amphotericin B.Liposomes: realizing their promise.Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.Amphotericin B lipid complex therapy of experimental fungal infections in miceEffects of the aggregation state of amphotericin B on its toxicity to mice.Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.Occlusion of retinal vessels using targeted delivery of a platelet aggregating agent.Optimizing efficacy of amphotericin B through nanomodification.Systemic Candida infections.Evaluation of a murine model of hepatic candidiasis.Fungal infections in cancer patients.Hepatosplenic candidiasis in children with cancer. Three cases in leukemic children and a literature review.New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis.Liposomes as carriers of antimicrobial agentsPharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studiesComparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.Amphotericin B toxicity reduced by administration in fat emulsion.Rapid infusion of amphotericin B in dextrose.The past, present, and future uses of liposomes in treating infectious diseases.Development of liposomal amphotericin B formulation.Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.Successful management of sequential pulmonary infections in a cardiac transplant recipient.
P2860
Q26740363-928B367C-2A89-42D9-8518-99FFD31E14B8Q28318068-D4CCAEE8-D629-41FC-9D8F-977599A31C23Q28333669-788994A4-6B52-43CC-B24B-1EC6D8400889Q28361166-E5485812-74B6-4390-AE32-50B8FA0AF20FQ28369708-EAA02BD0-8896-4B9B-90CA-77FD3BA157A1Q30355939-4917CE2B-8748-485E-B71E-FDCC4ACECC66Q30452906-8735F689-D5B9-49C1-9890-1A0F2C1B999DQ32052950-367F8922-2363-4FE3-9CFC-6A7207BDAB76Q33641360-FFB53F2A-FB3B-4A00-84B6-C82BB2555297Q33749111-43BA37C2-87CE-4A3D-85A5-8A5CE65B2DF6Q35118404-A926CE91-AEF5-4593-AA96-44FF118FFA8FQ35126170-3DC1A384-5817-4B0B-AA16-AE4EE56B79DFQ35130708-9649D820-E58E-432A-A82A-5DDB7A39EE7DQ35244959-9AC80499-2F61-49F4-88A7-FE9947D9A08DQ35249721-E7EB546D-19C7-42AE-9501-A86C09E5E770Q35325145-CD497377-A1F8-482A-ACB2-6F62B5D9194BQ35372581-92AC30E6-85D4-444B-984F-3A09B4563279Q35550017-543F721B-CB6A-4B16-9147-8C09AD8C9F06Q35824054-EACE5BC0-FE72-457E-BB28-C8DD8570D5FCQ36753279-AE0F8094-03E6-4CE6-A35A-EB95553AECDAQ36757947-DDF17F95-A3A8-489F-A47C-F53269A89ABFQ36758184-BAD7AC71-F97F-435F-92D6-570C3E262AE4Q36758404-80A281B7-8F76-4DB4-8501-A63F568C36CFQ36783024-17516F51-7DA8-47FB-87BE-E4807F5EABB2Q36920328-CD7D18F7-05AD-427A-9F32-B517E11BB222Q36987671-C3A460DD-FB3B-4360-B8AE-DF43D7384A71Q37188070-E4B81359-B2DA-4965-8235-A3F8C5B8A4FBQ37220788-76F3D894-D100-4FE6-81E0-2A4C2CE09F4BQ37951562-2C9F3CA5-EEE0-4984-A29E-98DF6D94221BQ37987555-6E827A27-63B9-4BB3-8C03-236B79551CDAQ39661451-85119F57-D0A9-4379-A383-DD604D3187E2Q39785066-ADCB53DF-3416-4EAA-9070-87E32FBCC485Q40085689-46244070-63C7-41CA-968C-B2F460A8FD0DQ40287352-8D146A1F-C952-4991-AB0D-5A40184B61DFQ40471190-623E47FA-62B9-4226-9379-0E29F1A0C444Q40471207-09D10E47-1D00-429B-851A-F41E41F94BE2Q40530985-9D06D13E-A225-4441-AA25-0C373657A9C0Q40639958-873FBADF-E507-4B05-BBC5-5343B5035185Q41668011-78751D71-F03B-4520-98B5-FA04B2BD5E4FQ42160869-A5B8E17E-8232-4C04-857A-ABF0003A51CD
P2860
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@en
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@nl
type
label
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@en
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@nl
prefLabel
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@en
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@nl
P2093
P356
P1476
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
@en
P2093
G Lopez-Berestein
L S Frankel
P304
P356
10.1200/JCO.1987.5.2.310
P407
P577
1987-02-01T00:00:00Z